Abstract
ONYX-015, dl1520, is an adenovirus that lacks the E1B 55K gene and therefore lacks the capacity to neutralize p53 during infection. This virus induces high levels of p53 and fails to grow efficiently in primary epithelial cells. However, it does replicate in many tumor cells, including those expressing wild-type p53. In these cells, ONYX-015 fails to induce active p53. This is because the pathway from E1a to p53 is disrupted through loss of p14ARF. We propose that high levels of Mdm2 activity resulting from loss of p14ARF, and high levels of Mdm2 protein resulting from activated Ras prevent accumulation of functional p53 during infection of tumor cells that retain wild-type p53.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Babiss LE, Ginsberg HS and Darnell Jr JE. . 1985 Mol. Cell. Biol. 5: 2552–2558.
Beltz GA and Flint SJ. . 1979 J. Mol. Biol. 131: 353–353.
Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A and McCormick F. . 1996 Science 274: 373–376.
Chiou SK and White E. . 1997 J. Virol. 71: 3515–3525.
de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ and Lowe SW. . 1998 Genes Dev. 12: 2434–2442.
Goodrum FD and Ornelles DA. . 1998 J. Virol. 72: 9479–9490.
Harada JN and Berk AJ. . 1999 J. Virol. 73: 5333–5344.
Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD and Kirn DH. . 1997 Nat. Med. 3: 639–645.
Howley PM, Munger K, Werness BA, Phelps WC and Schlegel R. . 1989 Princess Takamatsu Symp. 20: 199–206.
Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK and Kirn DH. . 2000 Nat. Med. 6: 879–885.
Ries SJ, Brandts CH, Chung AS, Biederer CH, Hann BC, Lipner EM, McCormick F and Michael Korn W. . 2000a Nat. Med. 6: 1128–1133.
Ries SJ, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T, McMahon M, Oren M and McCormick F. . 2000b Cell 103: 321–330.
Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M and zur Hausen H. . 1998 J. Virol. 72: 9470–9478.
Rubenwolf S, Schutt H, Nevels M, Wolf H and Dobner T. . 1997 J. Virol. 71: 1115–1123.
Sarnow P, Hearing P, Anderson CW, Halbert DN, Shenk T and Levine AJ. . 1984 J. Virol. 49: 692–700.
Sherr CJ. . 1998 Genes Dev. 12: 2984–2991.
Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH and Peters G. . 1998 EMBO J. 17: 5001–5014.
Turnell AS, Grand RJA and Gallimore PH. . 1999 J. Virol. 73: 2074–2083.
Wildner O, Morris JC, Vahanian NN, Ford Jr H, Ramsey WJ and Blaese RM. . 1999 Gene Ther. 6: 57–62.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McCormick, F. ONYX-015 selectivity and the p14ARF pathway. Oncogene 19, 6670–6672 (2000). https://doi.org/10.1038/sj.onc.1204096
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204096
Keywords
This article is cited by
-
Oncolytic Viruses in the Treatment of Cancer: A Review of Current Strategies
Pathology & Oncology Research (2012)
-
Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver
Cancer Gene Therapy (2007)
-
Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin
Cancer Gene Therapy (2005)
-
Tumor-specific intravenous gene delivery using oncolytic adenoviruses
Cancer Gene Therapy (2005)
-
Oncolytic viruses
Nature Reviews Cancer (2002)
